^<90>Y Ibritumomab Tiuxetan (Y2B8, Zevalin) Radioimmunotherap (RIT) Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkins Lymphoma (B-NHL) Pretreated with Rituximab-Containing Chemotherapy (R-Chemo) : Japanese Multicenter Phase II Study

• OGURA M

収録刊行物

• Blood

  Blood 2006

詳細情報

• CRID: 1570291225662687104
• NII論文ID: 10021933019
• データソース種別:
  • CiNii Articles